Harmony Biosciences Appoints Peter Anastasiou as CEO as Jeffrey Dayno Plans Retirement

Plymouth Meeting, PA, October 12, 2026 (Harmony Biosciences) -- Harmony Biosciences Holdings, Inc. has appointed Peter Anastasiou, its current Senior Executive Vice President and Chief Operating Officer and a former board member, as President and Chief Executive Officer, effective January 1, 2027. He will succeed Jeffrey M. Dayno, M.D., who will retire on December 31, 2026, after nine years with the company and serve as a non-executive advisor throughout 2027 to support the leadership transition. Anastasiou brings more than three decades of biopharmaceutical experience, including leadership roles at Capsida Biotherapeutics and Lundbeck. The transition comes as Harmony advances its central nervous system (CNS) drug pipeline, expands its pitolisant franchise, and maintains its 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion.

Read full article here.